Email this article Low intensity shock wave therapy for erectile dysfunction: 6 months followup results
- Authors: Korneyev I.A.1, Telegin I.V.1, Davydov I.V.1, Matveev A.V.1, Rubanov D.V.1, Al-Shukri S.H.1
-
Affiliations:
- I.P. Pavlov First Saint Petersburg State Medical University
- Issue: Vol 7, No 3 (2017)
- Pages: 5-13
- Section: Articles
- URL: https://journals.rcsi.science/uroved/article/view/7094
- DOI: https://doi.org/10.17816/uroved735-13
- ID: 7094
Cite item
Full Text
Abstract
Introduction. Low intensity extracorporeal shock wave therapy (ESWT) is a novel promising method of treatment for men with erectile dysfunction (ED). The efficacy of ESWT is not clearly determined and need further investigation.
Aim of the study: To investigate 6 months followup efficacy and safety results from ESWT trial in patients with ED.
Patients and methods. This open-label, longitudinal observational study investigated 6 months followup results in 19 men (mean age = 59.5 years) with organic ED (including 6 (32%) patients with type 2 diabetes mellitus and 6 (32%) patients after nerve-sparing radical prostatectomy) treated with 5-session weekly ESWT protocol using DornierAries delivery system (7500 shock waves, 1500 each session, 4 Hz). Information about adverse events was recorded. Effectiveness was assessed according to the International Index of Erectile Function and Sexual Health Inventory for Men after the 5th ESWT session and also in 1, 3 and 6 months.
Results. No patient reported treatment-related adverse events. In 12 (63%), 11 (57%), 11 (57%) and 9 (47%) patients IIEF increased after the 5th ESWT session (also in 2 (33%) men with ED caused by radical prostatectomy), and in 1, 3, 6 months after treatment respectively, so the mean IIEF score in the group has become higher (p = 0.003, p = 0.050, p = 0.022, р > 0.1 respectively) as well as the IIEF general satisfaction domain score (p = 0.006 и p = 0.014, р = 0.011 и p = 0.028, respectively). Mean SHIM score growth was significantly higher after the 5th ESWT session only (р = 0.020), also in patients with diabetic ED (р = 0.041). Individual variability of both IIEF and SHIM scores after treatment was high, with IIEF lower in patients with advanced age (р = 0.015).
Conclusions. In 6 months followup ESWT was safe in all and effective in many patients with ED. High individual variability of treatment efficacy needs further evaluation.
Full Text
##article.viewOnOriginalSite##About the authors
Igor A. Korneyev
I.P. Pavlov First Saint Petersburg State Medical University
Author for correspondence.
Email: iakorneyev@yandex.ru
doctor of medical science, professor
Russian Federation, 6/9, Lva Tolstogo street, St. Petersburg, 197089Ivan V. Telegin
I.P. Pavlov First Saint Petersburg State Medical University
Email: itelegins@gmail.com
student
Russian Federation, 6/9, Lva Tolstogo street, St. Petersburg, 197089Ivan V. Davydov
I.P. Pavlov First Saint Petersburg State Medical University
Email: iakorneyev@yandex.ru
student
Russian Federation, 6/9, Lva Tolstogo street, St. Petersburg, 197089Artem V. Matveev
I.P. Pavlov First Saint Petersburg State Medical University
Email: iakorneyev@yandex.ru
clinical resident
Russian Federation, 6/9, Lva Tolstogo street, St. Petersburg, 197089Dmitrij V. Rubanov
I.P. Pavlov First Saint Petersburg State Medical University
Email: iakorneyev@yandex.ru
clinical resident
Russian Federation, 6/9, Lva Tolstogo street, St. Petersburg, 197089Salman H. Al-Shukri
I.P. Pavlov First Saint Petersburg State Medical University
Email: alshukri@mail.ru
doctor of medical science, professor, head of the department
Russian Federation, 6/9, Lva Tolstogo street, St. Petersburg, 197089References
- Корнеев И.А., Алексеева Т.А., Аль-Шукри С.Х., и др. Детерминанты риска развития эректильной дисфункции мужчин в Российской Федерации: анализ результатов эпидемиологического исследования // Урология. – 2014. – № 3. – С. 26–31. [Korneev IA, Alekseeva TA, Al-Shukri SKh, et al. Determinants of risk of the development of erectile dysfunction in the Russian Federation: analysis of epidemiological studies. Urologiia. 2014;(3):26-31. (In Russ.)]
- Lewis RW. Epidemiology of erectile dysfunction. Urol Clin North Am. 2001;28(2):209-216. doi: 10.1016/S0094-0143(05)70132-4.
- Hatzimouratidis K, Amar E, Eardley I, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010;57(5):804-814. doi: 10.1016/j.eururo.2010.02.020.
- Young SR, Dyson M. The effect of therapeutic ultrasound on angiogenesis. Ultrasound Med Biol. 1990;16:261-269. doi: 10.1016/0301-5629(90)90005-W.
- Gotte G, Amelio E, Russo S, et al. Short time non-enzymatic nitric oxide synthesis from L-arginine and hydrogen peroxide induced by shock waves treatment. FEBS Lett. 2002;520(1-3):153-155.
- Nurzynska D, Di Meglio F, Castaldo C, et al. Shock waves activate in vitro cultured progenitors and precursors of cardiac cell lineages from the human heart. Ultrasound Med Biol. 2008;34(2):334-342. doi: 101016/j.ultrasmedbio.2007.07.017.
- Nishida T, Shimokawa H, Oi K, et al. Extracorporeal cardiac shock wave therapy markedly ameliorates ischemia-induced myocardial dysfunction in pigs in vivo. Circulation. 2004;110(19):3055-3061. doi: 10.1116/01.CIR.0000148849.51177.97.
- Liu J, Zhou F, Wang L, et al. Evaluation of the effect of different doses of low-energy shock wave therapy on the erectile function of streptozotocin (STZ)-induced diabetic rats. Int J Mol Sci. 2013;14(5):10661-10673. doi: 10.3390/ijms140510661.
- Zou ZJ, Tang LY, Liu ZH, et al. Short-term efficacy and safety of low-intensity extracorporeal shockwave therapy in erectile dysfunction: a systematic review and meta-analysis. Int Braz J Urol. 2017;43;Apr 6. doi: 10.1590/S1677-5538.IBJU.2016.0245.
- Clavijo RI, Kohn TP, Kohn JR, Ramasamy R. Effects of Low-Intensity Extracorporeal Shockwave Therapy on Erectile Dysfunction: A Systematic Review and Meta-Analysis. J Sex Med. 2017;14(1):27-35. doi: 10.1016/j.jsxm.2016.11.001.
- Angulo JC, Arance I, de Las Heras MM, et al. Efficacy of low-intensity shock wave therapy for erectile dysfunction: A systematic review and meta-analysis. Actas Urol Esp. 2016;Aug 9. doi: 10.1016/j.acuro.2016.07.005.
- Vardi Y, Appel B, Kilchevsky A, et al. Does low intensity extracorporeal shock wave therapy have a physiological effect on erectile function? Short-term results of a randomized, doubleblind, sham controlled study. J Urol. 2012;187(5):1769-1775. doi: 10.1016/j.juro.2011.12.117.
- Bechara A, Casabe A, De Bonis W, Gomez Ciciclia P. Twelve-month efficacy and safety of low-intensity shockwave therapy for erectile dysfunction in patients who do not respond to phosphodiesterase type 5 inhibitors. Sex Med. 2016;4(4):e225-e232. doi: 10.1016/j.esxm.2016.06.001.
- Hisasue S, China T, Horiuchi A, et al. Impact of aging and comorbidity on the efficacy of low-intensity shockwave therapy for erectile dysfunction. Int J Urol. 2016;23(1):80-84. doi: 10.1111/iju.12955.
- Lu Z, Lin G, Reed-Maldonado A, et al. Low-intensity extracorporeal shock wave treatment improves erectile function: a systematic review and meta-analysis. Eur Urol. 2017;71(2):223-233. doi: 10.1016/j.eururo.2016.05.050.
- Assaly-Kaddoum R, Giuliano F, Laurin M, et al. Low intensity extracorporeal shock wave therapy improves erectile function in a model of type II diabetes independently of NO/cGMP pathway. J Urol. 2016;196(3):950-956. doi: 10.1016/j.juro.2016.03.147.
- Li H, Matheu MP, Sun F, et al. Low-energy shock wave therapy ameliorates erectile dysfunction in a pelvic neurovascular Injuries rat model. J Sex Med. 2016;13(1):22-32. doi: 10.1016/j.jsxm.2015.11.008.
- Gruenwald I, Kitrey ND, Appel B, Vardi Y. Low-Intensity Extracorporeal Shock Wave Therapy in Vascular Disease and Erectile Dysfunction: Theory and Outcomes. Sex Med Rev. 2013;1(2):83-90. doi: 10.1002/smrj.9.
- Srini VS, Reddy RK, Shultz T, et al. Low intensity extracorporeal shockwave therapy for erectile dysfunction: a study in an Indian population. Can J Urol. 2015;22(1):7614-7622.
- Yee C, Chan E, Hou SM, et al. Extracorporeal shock wave therapy in the treatment of erectile function. A prospective, randomized, double-blinded, placebo, controlled study. Int J Urol. 2014;21(10):1041-1045. doi: 10.1111/iju.12506.
Supplementary files
